Inloggad som:

Dreamm 5

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Dreamm 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
PLACEHOLDER
patienterna får immunterapi och antikropp.
Mer information om studien för vårdgivare
Behandling
Fas 1-2
Palliativ
Företag
https://clinicaltrials.gov/ct2/show/NCT04126200?term=DREAMM-5&draw=2&rank=1#contacts

Studien ändrades senast av: studyjohanna (2019-12-07)

Tillbaka till listan